1.Shoulder Joint Motion Analysis of Daily Living Activities Using a Global Coordinate System
Yukiya INOUE ; Mayumi KIHARA ; Junko YOSHIMURA ; Naoki YOSHIDA ; Kenji MATSUMOTO ; Tomosaburo SAKAMOTO ; Kazuhisa DOMEN
The Japanese Journal of Rehabilitation Medicine 2013;50(10):840-844
Objective : With clinical application in mind, we developed a method to measure the movement of a selected joint three-dimensionally as a conic domain (joint sinus cone). The method was applied to shoulder joint motion during daily living activities exercises in a group of hemiparetic poststroke patients. The results were compared to the exercise range of physically unimpaired persons. Methods : The subjects dressed in jackets and performed certain other tasks in a sitting position and the range of motion of the shoulder joint in three dimensions was measured using a 6-dimensional electromagnetic tracking system. Measurement results were analyzed with a plane display using a Lambert Azimuthal equal area. Results : This method was able to determine findings difficult to see with the naked eye, such as the narrow range of motion in a paralyzed shoulder joint and poor functionality also in the contralateral shoulder. Conclusion : The dressing measurement was achieved using magnetic measurement equipment. By displaying the results through a map projection it was possible to appreciate the whole range of the motion. Because this method facilitates the expression of complex joint exercise ranges, it will be useful in the analysis of daily behavior restrictions due to impairment.
2.No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an Selective Serotonin Reuptake Inhibitor or Serotonin Norepinephrine Reuptake Inhibitor and the Brain-Derived Neurotrophic Factor (Val66Met) Polymorphism in Refracto.
Reiji YOSHIMURA ; Taro KISHI ; Hikaru HORI ; Atsuko IKENOUCHI-SUGITA ; Wakako UMENE-NAKANO ; Asuka KATSUKI ; Kenji HAYASHI ; Nakao IWATA ; Jun NAKAMURA
Clinical Psychopharmacology and Neuroscience 2012;10(1):49-53
OBJECTIVE: This study examined the association between the brain-derived neurotrophic factor (BDNF) (Val66Met) polymorphism and the response to the addition of an atypical antipsychotic drug to a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) in treatment-refractory depression. METHODS: The study enrolled 64 patients meeting the Diagnostic and Statistical Manual of Mental Disorders-IV criteria for major depressive disorder who were treated with at least two courses of a single antidepressant, but who had Hamilton Depression Rating Scale (HAMD-17) scores > or =15 points that were reduced less than 50% over at least a 4-week treatment period. There were 24 males and 40 females (age range 27-68 years; mean+/-SD, 48+/-13 years). The patients' clinical improvement was evaluated using the HAMD-17. Patients with at least a 50% decrease in the HAMD-17 score were defined as responders. Serum BDNF levels were assayed using enzyme-linked immunosorbent assays and the presence of the BDNF (Val66Met) polymorphism was determined using the TaqMan genotyping assay. RESULTS: No correlation was found between the BDNF (Val66Met) polymorphism and a positive response to adding an atypical antipsychotic drug. No differences were observed in the changes in the serum BDNF levels and HAMD-17 scores between Val66Val and Met-carriers. In addition, in patients who experienced remission, the atypical antipsychotic drug was discontinued after at least 3 months of treatment and the patients were then followed for 1 year; 14 of 27 patients (52%) relapsed within 1 year. CONCLUSION: These results suggest that the BDNF (Val66Met) polymorphism is not associated with the response to the augmentation of a SSRI or SNRI with an atypical antipsychotic drug, and that the combination of an atypical antipsychotic drug and a SSRI or SNRI should be continued for 3 months or more in refractory depressed patients in the Japanese population.
Asian Continental Ancestry Group
;
Brain-Derived Neurotrophic Factor
;
Depression
;
Depressive Disorder, Major
;
Depressive Disorder, Treatment-Resistant
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Humans
;
Male
;
Norepinephrine
;
Serotonin
3.Follow-up Study on Electroconvulsive Therapy in Treatment-resistant Depressed Patients after Remission: A Chart Review.
Yuki TOKUTSU ; Wakako UMENE-NAKANO ; Takahiro SHINKAI ; Reiji YOSHIMURA ; Tatsuya OKAMOTO ; Asuka KATSUKI ; Hikaru HORI ; Atsuko IKENOUCHI-SUGITA ; Kenji HAYASHI ; Kiyokazu ATAKE ; Jun NAKAMURA
Clinical Psychopharmacology and Neuroscience 2013;11(1):34-38
OBJECTIVE: Electroconvulsive therapy (ECT) has proven to be effective in treatment-resistant depression (TRD). In recent reports, 70% to 90% of patients with TRD responded to ECT. However, post-ECT relapse is a significant problem. There are no studies investigating risk factors associated with reintroducing ECT in depressive patients after remission previously achieved with former ECT. The aim of the present study is to examine such risk factors using a sample of TRD patients. METHODS: We conducted a chart review to examine patient outcomes and adverse events over short- and long-term periods. Forty-two patients met the criteria for major depressive disorder. RESULTS: The response rate was 85.7% (36/42). There were no significant differences in the baseline characteristics of patients exhibiting remission, response or non-response. The rate of adverse events was 21.4% (9/42). Among 34 patients who were available for follow-up, 18 patients relapsed (relapse rate, 52.9%), and 6 patients were reintroduced to ECT. The patients' age and age of onset were significantly higher in the re-ECT group than non re-ECT group. CONCLUSION: Our results suggest that older age and older age of onset might be considered for requirement of re-ECT after remission previously achieved with former ECT.
Age of Onset
;
Aging
;
Depression
;
Depressive Disorder, Treatment-Resistant
;
Electroconvulsive Therapy
;
Follow-Up Studies
;
Humans
;
Recurrence
;
Risk Factors
4.Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries.
Taku KOBAYASHI ; Tadakazu HISAMATSU ; Yasuo SUZUKI ; Haruhiko OGATA ; Akira ANDOH ; Toshimitsu ARAKI ; Ryota HOKARI ; Hideki IIJIMA ; Hiroki IKEUCHI ; Yoh ISHIGURO ; Shingo KATO ; Reiko KUNISAKI ; Takayuki MATSUMOTO ; Satoshi MOTOYA ; Masakazu NAGAHORI ; Shiro NAKAMURA ; Hiroshi NAKASE ; Tomoyuki TSUJIKAWA ; Makoto SASAKI ; Kaoru YOKOYAMA ; Naoki YOSHIMURA ; Kenji WATANABE ; Miiko KATAFUCHI ; Mamoru WATANABE ; Toshifumi HIBI
Intestinal Research 2018;16(2):168-177
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.
Asian Continental Ancestry Group
;
Colectomy
;
Colitis, Ulcerative
;
Colorectal Neoplasms
;
Consensus
;
Crohn Disease
;
Disease Management*
;
Disease Progression
;
Early Intervention (Education)
;
Epidemiology
;
Expert Testimony
;
Gastrointestinal Tract
;
Hospitalization
;
Humans
;
Inflammatory Bowel Diseases*
;
Japan*
;
Prevalence
;
Prognosis
5.Two Cases of Bioprosthetic Valve Stenosis of the Aortic Valve Position Found on Weaning of a Nipro Left Ventricular Assist Device
Takashi SHUTO ; Hirofumi ANAI ; Tomoyuki WADA ; Hideyuki TANAKA ; Madoka KAWANO ; Takayuki KAWASHIMA ; Tadashi UMENO ; Kenji YOSHIMURA ; Kaoru UCHIDA ; Shinji MIYAMOTO
Japanese Journal of Cardiovascular Surgery 2018;47(2):58-61
The first case was a 67-year-old woman. She had been given a diagnosis of fulminant myocarditis and received a biventricular assist device as a bridge to recovery. A Nipro ventricular assist device (VAD) was implanted into her left heart. She was also found to have moderate aortic insufficiency before the operation, so she received aortic valve replacement (AVR) with a bioprosthetic valve (CEP Magna Ease 21 mm) at the same time. Her cardiac function recovered gradually. Therefore, a weaning operation was scheduled for three months after the VAD implantation. However, her left ventricle motion was very poor when she was taken off of the extracorporeal circulation after removing the VAD, and transesophageal echocardiography (TEE) revealed severe bioprosthetic valve stenosis. When her heart was stopped again and the bioprosthetic valve was observed, the leaflets of the bioprosthetic valve were fused. Commissural fusion of bioprosthetic valve was able to be released using forceps, and the punnus extending under the leaflet was removed. In this way, the function of the bioprosthetic valve was restored. Her cardiac motion became good, and removal from extracorporeal circulation was easily achieved. She left the hospital 100 days after weaning from the VAD. The second case was a 68-year-old woman. She also had fulminant myocarditis. She underwent biventricular assist device implantation and AVR (CEP Magna Ease 19 mm). Her cardiac function recovered, and a weaning operation was scheduled on the 73rd-postoperative day. Preoperative TEE before the weaning of VAD showed severe bioprosthetic valve stenosis. The commissural fusion of the bioprosthetic valve was released and the punnus extending under the leaflet removed at the same time as the VAD was removed. Re-valve replacement was not required. We should therefore consider the possibility of bioprosthetic valve stenosis when VAD implantation and AVR with a bioprosthetic valve are performed at the same time in patients with an extremely reduced cardiac function.
6.Current Status and Issues of Education on Radiation Health Risk Science
Naoki MATSUDA ; Yoshishige URATA ; Masanobu KITAGAWA ; Masahiko AOKI ; Yoshio HOSOI ; Kenji NEMOTO ; Akira OHTSURU ; Tomonori ISOBE ; Hideyuki SAKURAI ; Kiyoshi MIYAKAWA ; Ryoichi YOSHIMURA ; Reiko KANDA ; Takashi KONDO ; Shunichi TAKEDA ; Takeshi TOUDO ; Kazuo AWAI ; Teruhisa TSUZUKI ; Takeshi NAGAYASU
Medical Education 2019;50(6):581-587
In accordance with the new model-core-curriculum for medical education, the current status of education about the science of radiation health was surveyed in all medical schools in Japan. Among the four learning points related to the “Biological effects of radiation and radiation hazards” , about half of the schools covered issues on “radiation and human body” and the “effect of medical radiation exposure” in one, or less than one, 60-minutes class, but did not touch on “radiation risk communication” and “radiological disaster medicine” . A significant deviation of human resources was also observed between schools. Learning tools such as presentation files and video content were preferred as education support materials. Therefore, development and distribution of the learning tools, especially in “radiation risk communication” and “radiological disaster medicine” , may be a first step to promoting high-quality education on the science of radiation health risk in each school’s curriculum.